MIRA Pharmaceuticals

Patient holding pill in hand
#Antidepressants #Depression #Major depressive disorder #MIRA Pharmaceuticals #MIRALOGX

Partners develop oral ketamine-based antidepressant for home use

MIRA Pharmaceuticals and MIRALOGX have formed a new partnership to develop and commercialise oral ketamine analog Ketamir-2, hoping to change the landscape of depressive disorder treatments. Ketamir-2 is a patent-pending compound under investigation to potentially deliver ultra-rapid antidepressant effects as early as four hours after dosing. After making its scientific… Read More

#Business & Investment #News